Administered systemically, both AD-MSCs and their EVs had beneficial effects in the model of ovalbumin-induced allergic asthma used herein, acting on the inflammatory process (reduction in total cell counts and eosinophil percentage in BALF, IL-5 levels in lung tissue, and percentage of CD3+CD4+ T cells in the thymus) and reversing tissue remodeling (decreased collagen fiber deposition in the lung parenchyma and airways, reduced TGF-β levels in lung tissue). The gene discussed is TGFB1; the disease is allergic asthma.